|1.||Warn, Peter A: 2 articles (02/2010 - 09/2005)|
|2.||Denning, David W: 2 articles (02/2010 - 09/2005)|
|3.||Sharp, Andrew: 2 articles (02/2010 - 09/2005)|
|4.||Morrissey, Graham: 2 articles (02/2010 - 09/2005)|
|5.||Graybill, J R: 1 article (06/2008)|
|6.||Lambros, C: 1 article (06/2008)|
|7.||Bocanegra, R: 1 article (06/2008)|
|8.||Najvar, L K: 1 article (06/2008)|
|9.||Najarian, N: 1 article (06/2008)|
|10.||Patterson, T F: 1 article (06/2008)|
06/01/2008 - "Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice."
03/01/2007 - "Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis."
03/01/2007 - "Aminocandin may be an effective addition to the arsenal of antifungal compounds for the treatment of candidiasis caused by fluconazole-resistant C. "
04/01/2003 - "We utilized a neutropenic murine model of disseminated candidiasis to describe the time course antifungal activity of HMR 3270, a new glucan synthase inhibitor. "
04/01/2003 - "In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model."
02/01/2010 - "Aminocandin at doses of > or =1mg/kg is highly effective in reducing mortality and organ burden in disseminated infection caused by ITC-susceptible and -resistant A. "
05/01/2006 - "Aminocandin (HMR-3702, IP-960) is an investigational agent, with published experience limited to in vitro studies and animal models of infection."
02/01/2010 - "The only fungicidal regimen was aminocandin 5mg/kg, which sterilised 40% and 50% of mice following infection with AF293 and AF91, respectively. "
02/01/2010 - "Following infection with AF91, only aminocandin at 5mg/kg and 1mg/kg i.v. yielded 100% survival, which was superior to ITC, aminocandin 0.25mg/kg and controls (all P<0.0001). "
02/01/2010 - "Following infection with AF293, only aminocandin 5mg/kg i.v. yielded 100% survival. "
06/01/2008 - "This study evaluated the therapeutic and prophylactic efficacy of single doses of aminocandin, a new echinocandin in preclinical development, in a murine model of invasive candidiasis. "
06/01/2008 - "These results demonstrate that single doses of aminocandin are effective as treatment and prophylaxis, and suggest that extended interval dosing may be a useful strategy for treating invasive candidiasis."
02/01/2010 - "Aminocandin (IP960; HMR3270; NXL201) is a new echinocandin with broad-spectrum in vitro activity against Aspergillus and Candida spp. We compared the activity of aminocandin with that of amphotericin B (AmB), itraconazole (ITC) and caspofungin (CAS) in murine models of disseminated aspergillosis against three strains of A. "
|2.||Amphotericin B (Amphotericin)